Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

Date Founded



255 State Street,9th floor,Boston, MA 02109

Type of Company


Employees (Worldwide)



Medical Products & Equipment

Company Description

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Contact Data
Trying to get in touch with decision makers at Pieris Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, President & Director

Senior Vice President, Corporate Operations & General Counsel

Senior Vice President & Chief Scientific Officer

Chief Medical Officer

Senior Vice President, Head of Clinical Development

Vice President & Head of Discovery & Alliance Management

Senior Vice President, Head of Translational Science

Senior Vice President, Head of Business Development

Vice President, Finance & Treasurer

Vice President, Human Resources

Board of Directors

Former President of Genzyme Europe & General Manager of Cardiovascular Business at Genzyme Corp.

President & Director at Synergie Lyon Cancer

Executive Vice President & Chief Medical Officer at Deciphera Pharmaceuticals LLC

Former President, Chief Executive Officer & Co-Founder at Arisaph Pharmaceuticals, Inc.

Founder at NextCure, Inc.

Chief Executive Officer, President & Director at Pieris Pharmaceuticals, Inc.

Advisor at Siamab Therapeutics, Inc.

Chief Medical Officer at Pieris Pharmaceuticals, Inc.

Former Vice President-Strategy, External Innovation & Science Policy at Sanofi

Paths to Pieris Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
Pieris Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Ecor1 Capital manages the EcoR1 Capital Fund LP, a fundamental long/short equity hedge fund focusing on investment opportunities in the biotechnology sector. The firm employs an innovative, process-driven approach that is based on a value philosophy which attempts to manage risk in the volatile biotechnology sector. The fund focuses on outliers not typically analyzed as part of value based diligence; human capital in addition to deep scientific and financial analysis. Ecor1 Capital is committed to going beyond the usual monetary investment in companies and engages directly with management to identify opportunities for efficiencies and growth, and where necessary, invests their own human capital resources to help mediate much of the risk that is inherent in the sector. The goal of combining this innovative perspective and process is generation of uncorrelated returns relative to the biotechnology sector and to the overall market.

Details Hidden

Aquilo Capital Management focuses on long/short investments in the stocks of companies in the life sciences and biotechnology sectors

Recent Transactions
Details Hidden

Pieris Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Pieris Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Pieris Pharmaceuticals, Inc. raised money in a private placement transaction

Transaction Advisors

Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock


Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock

Investment Advisor

Advised onPieris Pharmaceuticals, Inc. raised money in a private placement transaction

Managing Director, ECM

Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock


Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock

In-House Counsel

Advised onPieris Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants

Chief Financial Officer at Foghorn Therapeutics, Inc.


Former Senior Vice President at Trout Capital LLC


Vice President at MacDougall Biomedical Communications, Inc.


Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Key Stats and Financials As of 2018
Market Capitalization
Total Enterprise Value
Earnings Per Share
Enterprise Value Sales
TEVNet Income
Debt TEV
Total Equity
Total Debt
Net Profit
Three Year Compounded Annual Growth Rate Of Revenue
Five Year Compounded Annual Growth Rate Of Revenue
Technical University of Munich Computer Software | Munich, BV

TUM combines top-class facilities for cutting-edge research with unique learning opportunities for 37,343 students. TUM scientists are committed to finding solutions to the major challenges facing society as they move forward: • Health & Nutrition • Energy & Natural Resources • Environment & Climate • Information & Communications • Mobility & Infrastructure. TUM thinks and acts with an entrepreneurial spirit. Its aim is ambitious: to create lasting value for society through excellence in education and research, the active promotion of next-generation talent and a strong entrepreneurial spirit. All of which combine to make TUM one of Europe’s leading universities.

Enumeral Biomedical Holdings, Inc. Biotechnology | Arlington, MA

Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel antibody immunotherapies for the treatment of cancer and other diseases. It uses a human-driven immunoprofiling platform to identify and validate potential drug candidates in human immune microenvironments. The company was founded by Barry C. Buckland, John J. Rydzewski, Arthur H. Tinkelenberg in 2009 and is headquartered in Arlington, MA.

Sichuan Kelun Pharmaceutical Co., Ltd. Pharmaceuticals | Chengdu, SI

Sichuan Kelun Pharmaceutical Co., Ltd. engages in manufacture and sale of pharmaceutical products. Its products include IV Solutions, lyophilized, Sterile powders for injection, Tablets, Capsules, Oral Preparations, Injectable Powder, Antipsychotic, Respiratory System, Anti-pathogenic Microorganisms, APIs and Intermediates, SVP and medical devices. It also provides dialysis solutions, APIs, pharmaceutical packaging materials, medical devices, and antibiotic intermediates. The company was founded on May 29, 2002 and is headquartered in Chengdu, China.

Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Glenmark Pharmaceuticals Ltd. Pharmaceuticals - Mumbai, MA

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. It operates through the following segments: India, United States, Latin America, Europe, and Rest of the World. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Pieris Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Pieris Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Pieris Pharmaceuticals, Inc..